This new methodology is effective and faster than the PCR test, and opens up new options for detecting viruses such as SARS-CoV-2, the influenza A virus (H1N1) or the respiratory syncytial virus (RSV), a pathogen that affects newborn babies and requires careful differential diagnosis.

A scientific team has developed new hydrogels that serve as 3D culture systems for immune cells and organoids. They allow a higher rate of cell growth than traditional cultures. Among other applications, the team is focusing on growing cells for immunotherapies and obtaining mini-organs for pre-clinical trials.

Two new patents developed at the Institute of Advanced Chemistry of Catalonia (IQAC) from the CSIC have been licensed by Bicosome company. The new technological platforms made of only lipids and water do not need the presence of polymers, surfactants, or other gelling agents, bringing valuable benefits for skin care, especially sensitive skin.

The European project, Nabiheal, will work on the synthesis of advanced biomaterials as an alternative to silver-based dressings commonly used for wound healing. The new materials will be cheaper, safer and more sustainable.

An international team with CSIC participation has successfully developed and validated a biosensor for the ultra-sensitive detection of the hepatitis C virus (HCV). The device is based on graphene transistors that can detect key proteins of the virus. The results of this research appear in the journal Biosensors and Bioelectronics and the scientific team has already applied for the international patent of the invention.

A team from CSIC and the FINBA Foundation has identified three biomarkers that predict with high specificity and sensitivity the malignancy of a thyroid nodule, which could avoid many unnecessary surgeries. They are now looking for interested companies to develop specific kits.

CSIC has developed a pharmaceutical composition to treat uveal melanoma, a cancer that forms from melanin-producing cells in the eye. Although it has a low incidence, it is the most common eye cancer in adults. There are a few standard treatments for the primary tumour, but not for metastatic uveal melanoma of the eye.

Computational design has made it possible to create proteins that mimic the folded immunoglobulin structure of natural antibodies. They can be used as a basis for the development of tailor-made and more economical antibody-like drugs. These results open the door to the design of antibody-like proteins with tailored structures and better biophysical properties than current ones.